Transaction overview
NexPhase Capital (US) acquired an undisclosed stake in Magic Science Corporation (US), a leading FDA- and EPA-registered manufacturer of hypochlorous acid (HOCl). The transaction closed on August 26, 2025, with the exact deal value and equity stake not disclosed. Raymond James and Skytale Group served as financial advisors to Magic Science Corporation.
Deal structure and financing
The deal’s financing details, including equity and debt splits, have not been publicly disclosed. The lack of transparency around the specific terms suggests that this may be a closely held transaction between private parties with limited public involvement. Lead banks involved in arranging any necessary debt facilities for NexPhase Capital were Raymond James and Skytale Group as sell-side advisors, but no further information on leverage metrics or lock-up periods has been released. There is also no information available regarding potential IPO optionality.
Strategic context
NexPhase Capital's investment in Magic Science Corporation was driven by the latter’s rapid growth trajectory and its innovative approach to hypochlorous acid-based consumer products. Magic Science Corporation, founded in 2023, has built a profitable business around its flagship brand, Magic Molecule, which offers FDA-cleared antimicrobial skin sprays and other scientifically formulated skincare solutions. The company’s vertically integrated manufacturing process gives it control over production from solution formulation to packaging, ensuring high standards of purity and efficacy.
NexPhase Capital aims to leverage its operational expertise and financial resources to support further expansion for Magic Science Corporation in product development, retail distribution channels, and new consumer goods categories. For Magic Science Corporation, the partnership provides capital necessary to scale operations while also gaining access to NexPhase’s network of industry experts and potential partners. The deal is seen as a strategic move by both parties to capitalize on growing demand for effective, science-backed skincare solutions.
Regulatory path
No specific regulatory challenges or requirements were reported in connection with this transaction. Given the healthcare sector affiliation and cross-border potential between US entities, oversight might come from federal agencies like the FDA and EPA if further product approvals are sought. However, as of now, no significant regulatory hurdles have been identified that would impede the deal’s progress. Neither HSR filings nor EU antitrust reviews appear to be necessary given the undisclosed nature and likely scale of this transaction within the US healthcare market landscape.